Study of Arsenic Trioxide in Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Lung CancerCancer of LungPulmonary CancerPulmonary NeoplasmsCarcinoma, Small Cell
Interventions
DRUG

Arsenic Trioxide

Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects

Trial Locations (1)

30322

Emory University Winship Cancer Institute, Atlanta

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cephalon

INDUSTRY

collaborator

Teva Pharmaceuticals USA

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT01470248 - Study of Arsenic Trioxide in Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter